MARKET

STTK

STTK

Shattuck Labs, Inc.
NASDAQ
4.990
+0.370
+8.01%
After Hours: 4.970 -0.02 -0.40% 19:30 11/09 EST
OPEN
4.700
PREV CLOSE
4.620
HIGH
5.07
LOW
4.535
VOLUME
1.27M
TURNOVER
--
52 WEEK HIGH
8.33
52 WEEK LOW
1.720
MARKET CAP
508.19M
P/E (TTM)
-9.8422
1D
5D
1M
3M
1Y
5Y
1D
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Shattuck Labs (STTK) and Sarepta Therapeutics (SRPT)
TipRanks · 16h ago
Weekly Report: what happened at STTK last week (1102-1106)?
Weekly Report · 18h ago
Shattuck Labs’ RECEPTIVE Program Advances; Pantginis Maintains Buy Rating and $14 Price Target
TipRanks · 4d ago
Shattuck Labs reports Q3 EPS (14c), consensus (11c)
TipRanks · 4d ago
Shattuck Labs GAAP EPS of -$0.14 misses by $0.04
Seeking Alpha · 4d ago
*Shattuck Labs 3Q Research and Development Expenses $21.6M >STTK
Dow Jones · 4d ago
*Shattuck Labs 3Q Loss $25.2M >STTK
Dow Jones · 4d ago
Press Release: Shattuck Labs Reports Third -2-
Dow Jones · 4d ago
More
About STTK
Shattuck Labs, Inc. is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is engaged in developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease and other inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. It is conducting a Phase I clinical trial in healthy volunteers. It is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.

Webull offers Shattuck Labs Inc stock information, including NASDAQ: STTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STTK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading STTK stock methods without spending real money on the virtual paper trading platform.